UroGen Pharma's Upcoming Investor Engagements
UroGen Pharma Ltd. (NASDAQ: URGN), a leading biotechnology company committed to developing groundbreaking solutions for urothelial and specialty cancers, is gearing up for an exciting September filled with significant investor conferences. These events provide UroGen with an excellent platform to showcase their innovative therapies and engage with investors passionate about transformative healthcare.
Wells Fargo Healthcare Conference
Key Details
The first event on UroGen's calendar is the Wells Fargo Healthcare Conference scheduled for September 3rd at 2:15 PM ET. This fireside chat format allows company representatives to connect closely with attendees, discussing UroGen’s mission and the advancements in their product pipeline.
Cantor Fitzgerald Global Healthcare Conference
Conference Insights
Following closely, UroGen will present at the Cantor Fitzgerald Global Healthcare Conference on September 4th at 3:55 PM ET. This is another opportunity for UroGen to share their journey, emphasizing their commitment to providing better treatment options for patients with urothelial cancers.
H.C. Wainwright Annual Global Healthcare Conference
Ongoing Innovations
On September 8th at 9:00 AM ET, UroGen will also take part in the H.C. Wainwright 27th Annual Global Healthcare Conference. Each of these engagements not only highlights the innovative work UroGen is doing but also allows direct dialogue with investors who share an interest in advancing cancer treatment options.
Webcasts and Access to Presentations
For those unable to attend in person, UroGen will provide webcasts of these conferences, available through the Events section on the company’s Investor Relations site. This approach ensures that all interested investors can access the information and updates, promoting transparency and engagement.
About UroGen Pharma Ltd.
UroGen Pharma specializes in the development of advanced therapeutics for urothelial and specialty cancers. The mission pursued by UroGen is based on the belief that patients deserve better treatment options. The company's proprietary technology, RTGel®, is a reverse-thermal hydrogel designed for sustained release of medications, potentially enhancing the effectiveness of existing treatments.
With their first product approved for low-grade upper tract urothelial cancer, UroGen has made significant strides. Additionally, their second product stands as the first and only FDA-approved treatment for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. Both solutions are set to provide patients with non-surgical means of tumor ablation, demonstrating UroGen's commitment to innovation in cancer therapy.
Contact UroGen Pharma
If you have any inquiries, please reach out to:
Investors:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
Media:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Frequently Asked Questions
What types of cancers does UroGen Pharma focus on?
UroGen Pharma mainly focuses on urothelial and specialty cancers.
What is RTGel® technology?
RTGel® is a proprietary hydrogel-based platform designed for sustained release of medications, enhancing treatment effectiveness.
When will UroGen Pharma present at the investor conferences?
UroGen Pharma will present at various conferences in September, with specific dates ranging from September 3rd to September 8th.
How can I access the conference webcasts?
The webcasts will be available on UroGen's Investor Relations website following the events.
Who can I contact for investor-related inquiries?
You can contact Vincent Perrone, Senior Director of Investor Relations, via email or phone for any investor inquiries.
